Literature DB >> 27592246

Moyamoya syndrome causing stroke in young women with type 1 diabetes.

Jing W Hughes1, Jennifer A Wyckoff2, Abby S Hollander3, Colin P Derdeyn4, Janet B McGill5.   

Abstract

CONTEXT: Moyamoya syndrome is an idiopathic brain vasculopathy characterized by stenosis of major intracranial arteries. It often presents in patients with type 1 diabetes or thyroid disease and may have an autoimmune etiology. Moyamoya-related stroke poses a diagnostic challenge as initial symptoms and deficits vary greatly from classic ischemic stroke to encephalopathy, psychiatric, or seizure disorder. CASE DESCRIPTION: We report 4 patients with type 1 diabetes and other autoimmune diseases who developed moyamoya-related stroke at a young age. Despite having long-term diabetes, these patients exhibited no evidence of dyslipidemia or other typical risk factors for atherosclerosis which might contribute to premature stroke. Three of the four patients underwent revascularization surgery while one patient received conservative management. All patients had improved neurologic function after treatment, some with residual deficits.
CONCLUSION: We highlight the importance of recognizing moyamoya syndrome in patients with pre-existing autoimmune diseases such as type 1 diabetes, as prompt diagnosis and treatment can have major impact on patient outcome and quality of life.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmunity; Moyamoya; Stroke; Type 1 diabetes; Vasculopathy

Mesh:

Year:  2016        PMID: 27592246      PMCID: PMC5050134          DOI: 10.1016/j.jdiacomp.2016.08.004

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  16 in total

1.  Anti-alpha-fodrin autoantibodies in Moyamoya disease.

Authors:  Kouichi Ogawa; Shinji Nagahiro; Rieko Arakaki; Naozumi Ishimaru; Masaru Kobayashi; Yoshio Hayashi
Journal:  Stroke       Date:  2003-12-01       Impact factor: 7.914

2.  Diabetes mellitus and the Moyamoya syndrome.

Authors:  Regina S Bower; Grant W Mallory; Macaulay Nwojo; Fredric B Meyer; Yogish C Kudva
Journal:  Ann Intern Med       Date:  2012-09-04       Impact factor: 25.391

3.  Clinical features and outcome in North American adults with moyamoya phenomenon.

Authors:  Christopher L Hallemeier; Keith M Rich; Robert L Grubb; Michael R Chicoine; Christopher J Moran; DeWitte T Cross; Gregory J Zipfel; Ralph G Dacey; Colin P Derdeyn
Journal:  Stroke       Date:  2006-04-27       Impact factor: 7.914

4.  Moyamoya disease in China: its clinical features and outcomes.

Authors:  Lian Duan; Xiang-Yang Bao; Wei-Zhong Yang; Wan-Chao Shi; De-Sheng Li; Zheng-Shan Zhang; Rui Zong; Cong Han; Feng Zhao; Jie Feng
Journal:  Stroke       Date:  2011-10-20       Impact factor: 7.914

Review 5.  Moyamoya disease and moyamoya syndrome.

Authors:  R Michael Scott; Edward R Smith
Journal:  N Engl J Med       Date:  2009-03-19       Impact factor: 91.245

6.  Intraventricular hemorrhage and cerebral ischemic attacks in the presence of lupus anticoagulant mimicking moyamoya disease.

Authors:  S Fujiwara; M Miyazono; H Tsuda; M Fukui
Journal:  J Neurosurg Sci       Date:  1993-09       Impact factor: 2.279

7.  Long-term outcome in children with moyamoya syndrome after cranial revascularization by pial synangiosis.

Authors:  R Michael Scott; Jodi L Smith; Richard L Robertson; Joseph R Madsen; Sulpicio G Soriano; Mark A Rockoff
Journal:  J Neurosurg       Date:  2004-02       Impact factor: 5.115

8.  Moyamoya disease in a patient with schizophrenia.

Authors:  Dan I Lubman; Christos Pantelis; Patricia Desmond; Tina-Marie Proffitt; Dennis Velakoulis
Journal:  J Int Neuropsychol Soc       Date:  2003-07       Impact factor: 2.892

9.  Immune response profiling identifies autoantibodies specific to Moyamoya patients.

Authors:  Tara K Sigdel; Lorelei D Shoemaker; Rong Chen; Li Li; Atul J Butte; Minnie M Sarwal; Gary K Steinberg
Journal:  Orphanet J Rare Dis       Date:  2013-03-21       Impact factor: 4.123

10.  Neurocognitive dysfunction in adult moyamoya disease.

Authors:  Joanne R Festa; Lauren R Schwarz; Neil Pliskin; C Munro Cullum; Laura Lacritz; Fady T Charbel; Dana Mathews; Robert M Starke; E Sander Connolly; Randolph S Marshall; Ronald M Lazar
Journal:  J Neurol       Date:  2009-12-24       Impact factor: 4.849

View more
  4 in total

1.  rAAV8-733-Mediated Gene Transfer of CHIP/Stub-1 Prevents Hippocampal Neuronal Death in Experimental Brain Ischemia.

Authors:  Felipe Cabral-Miranda; Elisa Nicoloso-Simões; Juliana Adão-Novaes; Vince Chiodo; William W Hauswirth; Rafael Linden; Luciana Barreto Chiarini; Hilda Petrs-Silva
Journal:  Mol Ther       Date:  2016-12-31       Impact factor: 11.454

2.  Late-Onset T1DM and Older Age Predict Risk of Additional Autoimmune Disease.

Authors:  Jing W Hughes; Yicheng K Bao; Maamoun Salam; Prajesh Joshi; C Rachel Kilpatrick; Kavita Juneja; David Nieves; Victoria Bouhairie; Olivia J Jordan; Erica C Blustein; Garry S Tobin; Janet B McGill
Journal:  Diabetes Care       Date:  2018-10-25       Impact factor: 19.112

3.  The association between tinnitus and the risk of ischemic cerebrovascular disease in young and middle-aged patients: A secondary case-control analysis of a nationwide, population-based health claims database.

Authors:  Yung-Sung Huang; Malcolm Koo; Jin-Cherng Chen; Juen-Haur Hwang
Journal:  PLoS One       Date:  2017-11-02       Impact factor: 3.240

Review 4.  Western Moyamoya Phenotype: A Scoping Review.

Authors:  Raphael Miller; Santiago R Unda; Ryan Holland; David J Altschul
Journal:  Cureus       Date:  2021-11-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.